Prostate cancer remains one of the most prevalent malignancies affecting men worldwide, with androgen receptor signaling playing a pivotal role in disease progression and therapy resistance. Androgen deprivation therapies (ADT) have long been the frontline treatment; however, many patients eventually develop castration-resistant prostate cancer (CRPC), underscoring the urgent need for new molecular targets and therapeutic strategies. The study conducted by Zhang and colleagues brings to light the critical interplay between metabolites in the kynurenine pathway and AR signaling, potentially offering new hope for overcoming therapeutic resistance.

Central to their findings is quinolinic acid (QA), a metabolite produced downstream of 3-hydroxyanthranilic acid oxygenase (HAAO) activity within the kynurenine pathway of tryptophan metabolism. Quinolinic acid has traditionally been studied for its neurotoxic properties, but this research innovatively identifies QA as a key modulator within prostate cancer cells. The team demonstrated that HAAO expression is markedly elevated in prostate cancer tissues, correlating with advanced disease stages and poorer prognosis.

Mechanistically, quinolinic acid appears to fuel FDPS (farnesyl diphosphate synthase)-dependent androgen receptor signaling. FDPS is a crucial enzyme in the mevalonate pathway, responsible for the synthesis of isoprenoids, which are vital for protein prenylation and cellular proliferation. The researchers showed that elevated QA enhances FDPS activity, leading to increased AR signaling activity. This hyperactivation of AR signaling amplifies cancer cell growth and survival, facilitating resistance to standard therapies.

What makes this discovery particularly compelling is the demonstration that modulating levels of quinolinic acid can sensitize prostate cancer cells to combination therapeutic approaches. The study revealed that inhibiting HAAO or reducing quinolinic acid production diminishes FDPS-dependent AR signaling, thereby suppressing tumor cell proliferation and improving the effectiveness of anti-androgen drugs. These findings suggest a promising therapeutic window where targeting metabolic pathways can synergize with hormonal therapies to overcome resistance.

The implications of these results extend beyond a simple metabolic snapshot. They connect two major biological systems—the kynurenine pathway and the mevalonate pathway—each with independent significance in cancer biology but now linked through quinolinic acid’s regulatory effects. This metabolic crosstalk introduces a paradigm shift in how metabolic intermediates can be exploited to influence oncogenic signaling cascades.

Moreover, the study utilized a combination of advanced molecular techniques including transcriptomics, metabolomics, and functional assays in both in vitro and in vivo models. These comprehensive approaches validated the critical role of HAAO-derived quinolinic acid and its impact on FDPS expression and activity. Importantly, patient-derived xenografts and clinical data underscored the translational relevance of the findings, suggesting readiness for clinical exploration.

Therapeutically, the prospect of combining HAAO inhibitors or agents targeting quinolinic acid synthesis with established anti-androgen therapies such as enzalutamide marks a significant advancement. This combination strategy could potentially prevent or delay the onset of treatment resistance, a major hurdle in managing advanced prostate cancer. Additionally, the study hints at the broader possibility of targeting metabolic vulnerabilities in other androgen-driven cancers.

From a mechanistic perspective, the identification of quinolinic acid as an oncometabolite challenges previous notions relegating it to neurotoxicity roles. It invites further exploration of how metabolic byproducts can act as signaling molecules within the tumor microenvironment, influencing cancer cell behavior and treatment outcomes. This insight opens doors for novel biomarkers that can predict response to therapy and guide personalized medicine approaches.

Furthermore, the study paves the way to investigate whether similar metabolic dependencies exist in other malignancies where steroid hormone receptor signaling is critical. If so, the HAAO-FDPS-AR axis may become a universal target across multiple cancer types, broadening the scope of therapeutic interventions beyond prostate cancer alone.

On the molecular signaling axis, the team discovered that quinolinic acid’s impact on FDPS promotes AR nuclear translocation and transcriptional activity, leading to enhanced expression of AR target genes that drive proliferation and survival pathways. This detailed mechanistic insight provides concrete targets for pharmacological intervention and biomarker development.

This groundbreaking study also raises important questions about the metabolic plasticity of cancer cells and their ability to adapt biosynthetic pathways to sustain oncogenic signaling. Understanding how cancer cells leverage metabolites like quinolinic acid could illuminate resistance mechanisms and identify vulnerabilities exploitable by combination therapies.

In conclusion, the elucidation of HAAO-derived quinolinic acid as a central actor fueling FDPS-dependent androgen receptor signaling heralds a novel metabolic axis driving prostate cancer progression and therapy resistance. By bridging metabolic biochemistry and signal transduction, the research sets the stage for innovative treatment paradigms that combine metabolic inhibition with hormonal therapy, potentially transforming patient outcomes in prostate cancer and beyond.

Zhang and colleagues’ work exemplifies the power of integrative omics and translational research in unraveling complex cancer biology, inviting the scientific community to rethink how metabolic intermediates can be harnessed in the fight against malignancy. As research advances, the HAAO-quinolinic acid-FDPS-AR signaling axis may well become a cornerstone in precision oncology strategies targeting prostate cancer metabolism and hormone receptor signaling.

Subject of Research: Prostate cancer metabolism and androgen receptor signaling modulation by HAAO-derived quinolinic acid.

Article Title: HAAO-derived quinolinic acid fuels FDPS-dependent AR signaling and sensitizes prostate cancer to combination therapy.

Article References:
Zhang, H., Feng, T., Lv, M. et al. HAAO‑derived quinolinic acid fuels FDPS‑dependent AR signaling and sensitizes prostate cancer to combination therapy. Cell Death Discov. (2026). https://doi.org/10.1038/s41420-026-03203-x

Image Credits: AI Generated

DOI: https://doi.org/10.1038/s41420-026-03203-x

Prostate cancer remains one of the most common malignancies in men worldwide, frequently evolving into castration-resistant forms that defy standard hormone-based interventions. Researchers have long searched for agents capable of circumventing these resistance mechanisms. Curcumin’s therapeutic potential has garnered attention for its diverse molecular actions, but challenges persist in translating preclinical success into clinical efficacy due to its poor bioavailability.

This comprehensive review synthesizes 22 recent preclinical studies investigating curcumin’s molecular targets within prostate cancer models. Among the cardinal pathways influenced by curcumin are the PI3K/Akt/mTOR cascade, which regulates cell survival and metabolism, and the NF-κB signaling axis, a master regulator of inflammation and tumor progression. Additionally, curcumin modulates androgen receptor (AR) signaling, a critical driver of prostate tumor growth, thereby targeting the disease at multiple control nodes.

At the heart of curcumin’s anti-cancer arsenal lies its ability to induce apoptosis and necroptosis—programmed and inflammatory programmed cell death modalities, respectively. These processes effectively disrupt cancer cell proliferation and survival. Moreover, the compound enforces cell cycle arrest, preventing unchecked cellular division, while simultaneously suppressing cancer cell migration and angiogenesis, thereby stifling the cancer’s invasive and metastatic capabilities.

One of the formidable obstacles in realizing curcumin’s full therapeutic potential is its inherently poor pharmacokinetics. The compound’s low solubility and rapid metabolism curtail its bioavailability in systemic circulation, limiting the doses achievable within tumors. Overcoming these barriers has become a pivotal focus in curcumin research.

Innovative nanoformulation techniques have surged forward, revolutionizing curcumin delivery. The review highlights various nano-carriers such as Theracurmin®, a nanoparticle-based formulation that enhances systemic absorption, and PLGA-curcumin, which facilitates targeted delivery and sustained release within tumor microenvironments. These engineered nanosystems not only increase curcumin’s bioavailability but also ensure preferential accumulation inside malignant tissues, minimizing off-target effects.

Combining curcumin with established chemotherapeutic agents emerges as a synergistic strategy to potentiate anti-cancer efficacy. Specifically, co-administration with docetaxel—standard frontline chemotherapy for advanced prostate cancer—amplifies apoptosis induction and overcomes drug resistance mechanisms. Similarly, integration with natural compounds like quercetin or adjunct treatments such as phototherapy has demonstrated enhanced tumor suppression in preclinical models.

Despite these encouraging findings, a gap remains between bench and bedside. Clinical translation lags due to the complexity of prostate cancer biology, variations in curcumin formulations, and lack of large-scale clinical trials assessing optimized delivery systems. The review strongly advocates for rigorously designed clinical studies that incorporate advanced nanoformulations and combination regimens within well-characterized patient populations.

At the molecular level, curcumin acts as a pleiotropic agent. It simultaneously orchestrates downregulation of oncogenic signaling, dampens pro-inflammatory cytokines, and reinstates apoptotic pathways that cancer cells often evade. This multi-targeted mode of action positions curcumin as a powerful adjuvant capable of enhancing current therapeutic landscapes while potentially mitigating side effects.

The transition into nanomedicine represents a paradigm shift. By engineering curcumin into nanoparticles, liposomes, or polymeric micelles, researchers surmount solubility and stability issues, rendering the compound more bioavailable and pharmacodynamically potent. These breakthroughs herald a new era for natural product-based drug development.

Emerging data also underscore the importance of the tumor microenvironment in prostate cancer progression and therapy resistance. Curcumin’s ability to modulate angiogenesis disrupts the vascular support tumors depend upon, while its anti-migratory effects impede metastasis—a chief cause of mortality in advanced stages.

Moreover, curcumin’s impact on androgen receptor signaling reverberates profoundly given that AR drives prostate cancer pathogenesis. By inhibiting AR transcriptional activity, curcumin targets the disease’s hormonal underpinnings, offering an alternative or complementary pathway to traditional androgen deprivation therapies.

Encouragingly, the combination of curcumin with modern phototherapy harnesses oxidative stress mechanisms, selectively killing cancer cells while sparing normal tissues. This synergy paves the way for multimodal treatment regimens that could redefine the management of refractory prostate cancer.

While the preclinical landscape is rich with promise, the review cautions that therapeutic success hinges on meticulous clinical validation. Advanced nanoformulations must be evaluated in controlled trials to confirm safety, optimize dosage, and establish definitive clinical benefit. Only then can curcumin’s multifaceted potential be fully harnessed for patient care.

In summary, this systematic assessment conveys a compelling narrative: curcumin, historically valued for its medicinal properties, stands at the forefront of innovative prostate cancer therapies. Its ability to concurrently intercept multiple oncogenic pathways, combined with nanotechnology-driven delivery advancements, offers a beacon of hope against a tenacious disease. Future clinical endeavors will ultimately determine whether this golden spice can transform the therapeutic horizon for prostate cancer patients.

Subject of Research: Molecular mechanisms and nanoformulated delivery strategies of curcumin in prostate cancer treatment.

Article Title: Curcumin in prostate cancer: a systematic review of molecular mechanisms and nanoformulated therapeutic strategies

Article References:
Esmaeli, M., Dehghanpour Dehabadi, M. Curcumin in prostate cancer: a systematic review of molecular mechanisms and nanoformulated therapeutic strategies. BMC Cancer 25, 1609 (2025). https://doi.org/10.1186/s12885-025-15152-2

Image Credits: Scienmag.com

DOI: https://doi.org/10.1186/s12885-025-15152-2